Recent clinical studies surrounding Retatrutide , specifically the high-dose formulation branded as ZPHC, indicate a considerable benefit on weight reduction and associated chronic illnesses . Researchers believe that this dual compound, targeting both GLP-1 and GIP pathways , may provide a major